EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
|Articles|June 16, 2010
A to Z Accounting
Always make sure that you work all of your accounts each month.
Advertisement
Always make sure that you work all of your accounts each month. Don't ignore those patients listed at the end of the alphabet; instead, every other month, start with “Z.” Better yet, ignore the alphabet and work the biggest accounts first.
(Courtesy of
Advertisement
Related to this article
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
2
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
5